SCHEDULE: Trill AB and Jan Stahlberg Report 16.9% Stake in DiaMedica

Trill AB and Jan Stahlberg have reported a 16.9% beneficial ownership stake in DiaMedica Therapeutics Inc., holding 8,825,742 common shares.

Summary

• Trill AB and Jan Stahlberg, collectively referred to as Reporting Persons, beneficially own 8,825,742 Common Shares of DiaMedica Therapeutics Inc.
• This ownership represents 16.9% of the Issuer's outstanding Common Stock.
• The percentage is based on 52,077,439 shares outstanding as of November 10, 2025, as reported in DiaMedica's Form 10-Q for the quarter ended September 30, 2025.
• Trill AB is the record holder of the shares, and Jan Stahlberg is a Board Member and beneficial owner of Trill AB.
• Both Reporting Persons have shared voting power and shared dispositive power over all 8,825,742 shares.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. A significant 16.9% stake by a named entity and individual suggests a strong belief in the company's value, which can be reassuring to other investors, although it's a routine disclosure of existing ownership.

Positives

• A significant beneficial ownership stake of 16.9% by Trill AB and Jan Stahlberg indicates a strong conviction in DiaMedica Therapeutics Inc. from a major investor.
• The shared voting and dispositive power suggests a unified investment strategy from the reporting entities.

Negatives

• NA

Risks

• Concentrated ownership by a single entity or group, while potentially signaling confidence, could also lead to less liquidity for other shareholders if the reporting persons decide to divest a large portion of their holdings.
• The certification states the shares are not held for influencing control, but a 16.9% stake still provides significant influence in corporate matters, which could diverge from the interests of other shareholders.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant beneficial ownership filings like this Schedule 13G are common across all industries, including biotechnology. While this filing does not provide specific industry-related insights, a substantial stake by an institutional investor or a prominent individual can sometimes signal confidence in the company's long-term prospects within its sector, especially for a therapeutics company like DiaMedica.

Stakeholder Impact

• Shareholders: The disclosure of a significant beneficial owner can provide confidence and potentially influence market perception, as a large stake often implies a thorough due diligence process and long-term commitment.
• Company Management: Awareness of a large, concentrated ownership stake may influence strategic decisions, particularly if the beneficial owner is active or has a board presence (as Jan Stahlberg does).

Key Dates

Recommendation

The filing reports a significant existing beneficial ownership stake, which is a factual disclosure of an investor's position rather than new operational or financial news. While a large stake can be seen as a vote of confidence, it doesn't inherently change the company's fundamentals or immediate prospects. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current position while considering this ownership structure as part of their broader analysis of DiaMedica Therapeutics Inc.

Keywords

DiaMedica Therapeutics Inc., Trill AB, Jan Stahlberg, Beneficial Ownership, SEC Filing, Schedule 13G, Common Shares, Stockholm, Sweden, Biotechnology